<DOC>
	<DOCNO>NCT00955604</DOCNO>
	<brief_summary>To identify occurrence serotonin toxicity Parkinson 's Disease ( PD ) patient receive antidepressant therapy rasagiline , compare receive rasagiline without antidepressant medication compare PD patient receive antidepressant , rasagiline .</brief_summary>
	<brief_title>Azilect + Antidepressant Chart Review</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>1 . Male female patient diagnosis PD 2 . Rasagiline treatment mono adjunct therapy PD concomitant antidepressant medication ( SSRIs , SNRIs , St. John 's wort and/or TCAs ) time specify review period , OR Rasagiline treatment mono adjunct therapy PD without concomitant antidepressant medication ( SSRIs , SNRIs , St. John 's wort and/or TCAs ) time specify review period . OR Antidepressant therapy ( SSRIs , SNRIs , St. John 's wort and/or TCAs ) dopaminergic antiPD treatment besides rasagiline selegiline time specify review period 3 . Willing consent review office chart review record ER visit and/or hospitalization correspond review window , require 4 . Patients previously participate rasagiline clinical trial ( followup protocol ) eligible , provide receive antidepressant therapy trial participation . 5 . In addition criterion , group specific inclusion criterion state : Group R+AD : Enrollment group require patient must take rasagiline antidepressant ( SSRIs , SNRIs , St. John 's wort and/or TCAs , regardless indication ) within 14 day ( five week , fluoxetine precede rasagiline ) . Group R : Enrollment group require patient must least 2 month rasagiline use . Group AD : Patients must take approved dopaminergic medication PD . Enrollment group require patient must least 2 month treatment antidepressant medication . 1 . Use rasagiline indication PD 2 . Patients take monoamine oxidase inhibitor ( MAOI ) antidepressant and/or selegiline 3 . Inability unwillingness request record ER visit and/or hospitalization correspond review period .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Serotonin Toxicity</keyword>
	<keyword>Rasagiline</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Chart Review</keyword>
	<keyword>Retrospective</keyword>
</DOC>